News

In an observational study, investigators are looking at the role of antibody secreting plasmablasts and GC B cells induced by the COVID-19 vaccines.

MedShr Insights has developed an early warning system that applies natural language processing, artificial intelligence, and machine learnings.

The company’s IASAB will identify key business initiatives, ensuring they align with its strategic vision.

AAO develops task forces to evaluate academy, review outcomes in ophthalmology.

Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).

If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery offering people with wet AMD.

According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.

Postop management with long-term topical antibiotics is critical to successful device retention.

Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).

The American Medical Association is advocating equitable resource distribution of vaccinations to assist low-income countries.

According to investigators, infants may have an edge over adults, with babies demonstrating a stronger immune response to the SARS-CoV-2 virus.

According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

The US Supreme Court ruled Thursday that the Affordable Care Act remains valid, rejecting a claim by several states that a recent change to the law made it unconstitutional.

The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.

The American Academy of Ophthalmology is calling on its members to continue to build confidence in COVID-19 vaccines and encourage people to get vaccinated, including their staff.

Clearside Biomedical, Inc. reported today positive safety results from Cohort 1 of its ongoing OASIS phase1/2a clinical trial of CLS-AX for the treatment of wet AMD.

Classification criteria funded by the National Institutes of Health will facilitate clinical research for new therapies.

EyeGate Pharmaceuticals, Inc.'s lead product candidate is designed to treat dry eye disease-induced ocular surface inflammation.

Stuart will enroll 150 volunteers in the study, which is being conducted with the support of Stuart's strategic partner and CRO, Ora Clinical. ST-100 is based on PolyCol, the company's synthesized polypeptide tissue reparative platform.

Physicians want to make sure they see each their patient frequently enough not to miss important changes in eye disease.

According to the company, more than 400 eyes of patients from 12 European countries have been fitted with the TECNIS Eyhance Toric II IOL, with surgeons surveyed noting that their patients are pleased with the results.

Researchers seek to identify new serological biomarkers that could better characterize Sjogren’s syndrome and overcome the limitations of traditional antibodies.

According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.

More Americans have used and continue to use teleheath for mental health care. according to a recent online poll by the American Psychiatric Association.

Upsher-Smith Laboratories LLC and Rafarm SA have announced the U.S. commercial launch of moxifloxacin ophthalmic solution, USP 0.5% following a recent abbreviated new drug application (ANDA) approval by the FDA.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

A new report by George Washington University offers a snapshot of health care workers during the COVID-19 pandemic and offers recommendations to prepare for the future.

Vyluma Inc. will focus on the development and commercialization of therapies to treat ophthalmic diseases, including pediatric myopia.